抗肥胖药物市场规模、份额、成长分析（按药物类型、作用、剂量和地区划分）- 产业预测，2025 年至 2032 年

2023 年全球减肥药市场规模价值 37 亿美元，预计将从 2024 年的 46.7 亿美元成长到 2032 年的 302.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 26.3%。

世界肥胖联合会预测，2025年终，肥胖相关成本将飙升50%以上，达到约1.2兆美元。这一激增凸显了製药业对于开发有效的肥胖解决方案的重视。随着患者数量的增长和治疗率仍然较低，新参与企业面临着巨大的机会。肥胖意识倡议和支持性报销政策的建立可能会推动对该产品的需求。 COVID-19 疫情反而促进了已通过核准的减肥药物的销售量，因为与肥胖相关的健康风险日益增加，促使卫生组织发布管理指南。此外，由于封锁而导致久坐行为的增加可能会加剧对肥胖症治疗的需求，从而促进市场成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 专利分析
• 监管分析

抗肥胖药物市场规模（依药物类型划分）

• 市场概况
• 处方药
• 非处方药

抗肥胖药物市场规模（依功能划分）

• 市场概况
• 中枢抗肥胖药物
• 外周作用抗肥胖药物

抗肥胖药物市场规模（按剂量）

• 市场概况
• 口服
• 皮下

减肥药市场规模（依分销管道划分）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

减肥药市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Novo Nordisk A/S（Denmark）
• Eli Lilly and Company（USA）
• Roche Holding AG（Switzerland）
• Pfizer Inc.（USA）
• Currax Pharmaceuticals LLC（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Amgen Inc.（USA）
• AstraZeneca PLC（UK/Sweden）
• GlaxoSmithKline plc（UK）
• Sanofi SA（France）
• Rhythm Pharmaceuticals, Inc.（USA）
• Gelesis Holdings, Inc.（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Eisai Co., Ltd.（Japan）
• Orexigen Therapeutics, Inc.（USA）
• Zafgen Inc.（USA）（Ceased operations）
• VIVUS LLC（USA）（Acquired by Currax Pharmaceuticals）
• Cheplapharm Arzneimittel GmbH（Germany）
• KVK Tech Inc.（USA）

结论和建议

Global Anti Obesity Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 30.26 billion by 2032, growing at a CAGR of 26.3% during the forecast period (2025-2032).

The World Obesity Federation forecasts that obesity-related costs will surge by over 50%, reaching approximately $1.2 trillion by the end of 2025. This escalation emphasizes the pharmaceutical industry's focus on developing effective solutions to combat obesity. As the patient population grows and treatment rates remain low, there are significant opportunities for new entrants in the market. Initiatives aimed at educating the public about obesity and the establishment of supportive reimbursement policies are likely to drive product demand. The COVID-19 pandemic has paradoxically boosted sales of approved anti-obesity medications, as heightened health risks associated with obesity have prompted health organizations to issue management guidelines. Furthermore, increased sedentary behavior due to lockdowns has intensified the need for obesity treatments, potentially enhancing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti Obesity Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti Obesity Drugs Market Segmental Analysis

Global Anti Obesity Drugs Market is segmented by Drug Type, Action, Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Prescription Drug and Over the Counter Drugs. Based on Action, the market is segmented into Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs. Based on Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti Obesity Drugs Market

The global anti-obesity drugs market is significantly driven by escalating concerns regarding effective obesity management, propelled by the alarming rise in obesity rates among populations worldwide. Currently, the World Obesity Federation reports staggering figures of approximately 650 million adults and 120 million children grappling with obesity, leading to an annual expenditure of around US$ 2 trillion for obesity-related healthcare. Furthermore, the Centers for Disease Control and Prevention (CDC) indicates that 42.5% of adults in the United States are classified as obese. This escalating awareness, particularly in emerging economies, about the necessity of timely weight management is anticipated to further fuel the demand for anti-obesity medications in the market over the coming years.

Restraints in the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market faces significant restraints, despite the increasing prevalence of obesity worldwide. Treatment rates remain low, primarily due to a lack of awareness regarding weight management and widespread misconceptions about obesity. Our research indicates that only 2% of individuals with obesity receive prescription medication for their condition, reflecting low acceptance of these drugs, which hampers market growth. Additionally, the market is constrained by the limited number of key companies focused on developing obesity treatments and the adverse effects associated with these medications, further impeding broader adoption and expansion of anti-obesity solutions.

Market Trends of the Global Anti Obesity Drugs Market

The Global Anti-Obesity Drugs market is witnessing a significant trend towards the development of dual-action therapeutic compounds aimed at simultaneously addressing both Type 2 diabetes mellitus and obesity. This burgeoning focus is driven by the alarming increase in obesity rates and the corresponding prevalence of Type 2 diabetes, prompting pharmaceutical companies and researchers to innovate and create effective medications that tackle these interrelated health issues. With unhealthy dietary habits, sedentary lifestyles, and a growing obese population persisting as key challenges, the market is poised for substantial growth in the coming years, presenting lucrative opportunities for stakeholders in the healthcare sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis

Global Anti Obesity Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Prescription Drug
• Over the Counter Drugs

Global Anti Obesity Drugs Market Size by Action & CAGR (2025-2032)

• Market Overview
• Centrally Acting Anti-Obesity Drugs
• Peripherally Acting Anti-Obesity Drugs

Global Anti Obesity Drugs Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral Route
• Subcutaneous Route

Global Anti Obesity Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Anti Obesity Drugs Market Size & CAGR (2025-2032)

• North America (Drug Type, Action, Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Action, Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Action, Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Action, Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Action, Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Currax Pharmaceuticals LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gelesis Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orexigen Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zafgen Inc. (USA) (Ceased operations)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VIVUS LLC (USA) (Acquired by Currax Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cheplapharm Arzneimittel GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KVK Tech Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations